IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A composition, comprising:

a very low water-soluble drug; and

a porous silicon material;

wherein:

the composition is produced by treating a mixture comprising the very low water-soluble drug and the porous silicon material with a supercritical or subcritical carbon dioxide fluid;

the very low water-soluble drug has a solubility in water at 25 °C of less than 10 μg/mL prior to treatment;

the porous silicon material comprises at least one member selected from the group consisting of light anhydrous silicic acid, hydrated silicon dioxide, silicon dioxide, ~~or~~ and calcium silicate;

the porous silicon material is not a porous silica material having all of the following:

an average pore diameter of 1 to 20 ~~nm,~~ nm;

~~where a total pore volume of pores having a diameter falling within a range of ± 40% of the average pore diameter accounts for~~ 60% or more of a volume of all of the pores of the porous silica ~~material,~~ material have a diameter falling within a range of ± 40% of the average pore diameter; and

~~having~~ an X-ray diffraction pattern including one or more peaks at a diffraction angle (2θ) corresponding to d of 1 nm or more;

the porous silicon material has an average pore diameter of 1 to 500 nm;

the porous silicon material has a specific surface area of 100 to 1,800 m^2/g; and

the composition is suitable for oral administration.

Claims 2-6 (Cancelled).

Claim 7 (Previously Presented): The composition according to claim 1, wherein the porous silicon material has an average pore diameter of 2 to 200 nm.

Claims 8-9 (Cancelled).

Claim 10 (Previously Presented): The composition according to claim 1, wherein the porous silicon material has a specific surface area of 200 to 1,500 m^2/g.

Claim 11 (Previously Presented): The composition according to claim 1, wherein a ratio by weight of the very low water-soluble drug to the porous silicon material is 1:0.1 to 1:1,000.

Claim 12 (Previously Presented): The composition according to claim 1, wherein the very low water-soluble drug is 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one or prednisolone valerate acetate.

Claim 13 (Currently Amended): A drug product, comprising:

the composition according to claim 1; and

at least one additive.

Claim 14 (Withdrawn): A method for producing the composition according to claim 1, comprising:

placing the very low water-soluble drug and the porous silicon material in a pressure-resistant vessel;

filling the vessel with carbon dioxide;

maintaining the vessel at a temperature and pressure such that the carbon dioxide assumes the form of supercritical or subcritical fluid; and

discharging the carbon dioxide fluid from the vessel and collecting the resultant composition.

Claim 15 (Withdrawn): The method according to claim 14, wherein a ratio by weight of the very low water-soluble drug to the supercritical or subcritical carbon dioxide fluid is from 1:1 to 1:1,000,000.

Claim 16 (Withdrawn): The method according to claim 14, wherein maintaining the vessel comprises maintaining the vessel at temperature of from –40 to 100°C.

Claim 17 (Withdrawn): The method according to claim 14, wherein maintaining the vessel comprises maintaining the vessel at a pressure of from 1 to 50 MPa.

Claim 18 (Withdrawn): The method according to claim 14, wherein the very low water-soluble drug and porous silicon material are maintained in contact with the supercritical or subcritical carbon dioxide fluid for a period of from one minute to 24 hours.

Claim 19 (Withdrawn): A method for producing the composition according to claim 1, comprising:

placing the very low water-soluble drug and the porous silicon material in a pressure-resistant vessel;

maintaining the vessel at a temperature at which carbon dioxide is in a supercritical or subcritical state;

filling the vessel with carbon dioxide so as to attain a pressure such that the carbon dioxide assumes the form of a supercritical or subcritical fluid;

treating the drug and the porous silicon material with the supercritical or subcritical carbon dioxide fluid; and

discharging the carbon dioxide fluid from the vessel and collecting the resultant composition.

Claim 20 (Withdrawn): The method according to claim 19, wherein a ratio by weight of the very low water-soluble drug to the supercritical or subcritical carbon dioxide fluid is from 1:1 to 1:1,000,000.

Claim 21 (Withdrawn): The method according to claim 19, wherein treating the drug and the porous silicon material comprises treating at a temperature of from –40 to 100°C.

Claim 22 (Withdrawn): The method according to claim 19, wherein treating the drug and the porous silicon material comprises treating at a pressure of from 1 to 50 MPa.

Claim 23 (Withdrawn): The method according to claim 19, wherein treating the drug and the porous silicon material comprises treating for a period of from one minute to 24 hours.